Statistics from Altmetric.com
Receipt of timely and specialised care for the management of acute myocardial infarction (AMI) is associated with improved clinical outcomes. Yet, not all hospitals are equipped and/or enabled to provide specialised interventions, and as a result patients may be transferred between centres to access these services. Given that there may be shortfalls in local capacity to deliver a high-quality cardiovascular service for AMI that may drive the necessity for centralisation of services, there is also a large body of evidence that suggests that inter-hospital transfer for the treatment of AMI, particularly primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI), is strongly associated with reduced mortality. Overall, the evidence suggests that higher volume and PCI-capable centres have lower mortality rates and that transfer of patients to such centres, through coordinated networks of care, is safe and effective. Such a notion is supported by international guidelines.1
One of the earliest reports of inter-hospital transfer for AMI studied 104 patients with suspected AMI, between 1983 and 1984, who were transferred by an aeromedical team. There were no deaths during transfer, and 87% of patients survived to be discharged from hospital.2 In 2000, the PRimary Angioplasty in patients transferred from General community hospitals to specialised PTCA Units with or without Emergency thrombolysis (PRAGUE) study found that of the 300 study participants presenting to hospital within 6 h of symptom onset with AMI, those who were randomised to immediate transportation for primary angioplasty without pretreatment with thrombolysis less frequently had the primary composite endpoint of death, reinfarction or stroke at 30 days.3 Notably, these findings were upheld at 5 years from date of randomisation.4 Other studies have investigated the impact of inter-hospital transfer across a range …
Contributors All authors have contributed to the article and have read the final submitted version.
Funding CPG is funded by the National Institute for Health Research (NIHR/CS/009/004) as a Clinician Scientist and Honorary Consultant Cardiologist. MvL is funded by the British Heart Foundation (PG/13/81/30474) as a senior epidemiologist.
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.